Mitochondria and cancer: A growing role in apoptosis, Cancer cell metabolism and dedifferentiation

Advances in Experimental Medicine and Biology

Volumn 942, Issue , 2012, Pages 287-308

  Scatena, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antineoplastic agents; Cancer stem cell; Cell Transformation; Neoplasm metabolism; Neoplastic genetics; Tumor markers; Warburg effect

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CALCIUM; CALCIUM ION; ESTRADIOL; ETHINYLESTRADIOL; FIBRIC ACID DERIVATIVE; FUMARATE HYDRATASE; GLUTAMINASE; GLUTAMINASE 2; GLUTAMINE; GLUTATHIONE; HEAT SHOCK PROTEIN 22; HEAT SHOCK PROTEIN 90; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE ISOENZYME; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN MCL 1; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER INVASION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL STRESS; CELL TRANSFORMATION; CITRIC ACID CYCLE; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; GLYCOLYSIS; HUMAN; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; OXIDATIVE PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESPIRATORY CHAIN; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION;

APOPTOSIS; CELL DIFFERENTIATION; DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIA; MUTATION; NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84859898559     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-2869-1_13     Document Type: Article

References (123)

1. Alvero AB, Montagna MK, Holmberg JC et al (2011) Targeting the mitochondriaactivates two independent cell death pathways in the ovarian cancer stem cells. Mol Cancer Ther 10:1385-1393
2. Amuthan G, Biswas G, Ananadatheerthavarada HK et al (2002) Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinomaA549 cells. Oncogene 21:7839-7849
3. Balaban RS, Bader JP (1984) Studies on the relationship between glycolysis and (Na+ K+)-ATPase in cultured cells. Biochim Biophys Acta804:419-426
4. Bellance N, Lestienne P, Rossignol R (2009) Mitochondriafrom bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci 14:4015-4034
5. Bensaad K, Vousden KH (2007) P53: new roles in metabolism. Trends Cell Biol 17:286-291
6. Bottoni P, Giardina B, Martorana GE et al (2005) A two-dimensional electrophoresis preliminary approach to human hepatocarcinomadifferentiation induced by PPAR-agonists. J Cell Mol Med 9:462-467
7. Bottoni P, Giardina B, Vitali A et al (2009) A proteomic approach to characterizing ciglitazone-induced cancer cell differentiation in Hep-G2 cell line. Biochim Biophys Acta 1794:615-626
8. Brandon M, Baldi P, Wallace DC (2006) Mitochondrial mutations in cancer. Oncogene 25:4647-4662
9. Cadenas E (2004) Mitochondrial free radical production and cell signaling. Mol Aspects Med 25:17-26
10. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85-95
11. Calderwood SK, Khaleque MA, Sawyer DB et al (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31:164-172
12. Chen EI, Hewel J, Krueger JS et al (2007a) Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 67:1472-1486
13. Chen Y, Voegeli TS, Liu PP et al (2007b) Heat shock paradox and anew role of heat shock proteins and their receptors as anti-inflammation targets. Inflamm Allergy Drug Targets 6:91-100
14. Chen ZX, Velaithan R, Pervaiz S (2009) MitoEnergetics and cancer cell fate. Biochim Biophys Acta 1787:462-467
15. Cheng T, Sudderth J, Yang C et al (2011) Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci USA 108:8674-8679
16. Costello LC, Franklin RB (2005) Why do tumour cells glycolyse?: from glycolysis through citrate to lipogenesis. Mol Cell Biochem 280:1-8
17. Cuezva JM, Krajewska M, de Heredia ML et al (2002) The bioenergetic signature of cancer: amarker of tumor progression. Cancer Res 62:6674-6681
18. Cuezva JM, Chen G, Alonso AM et al (2004) The bioenergetic signature of lung adenocarcinomas is amolecular marker of cancer diagnosis and prognosis. Carcinogenesis 25:1157-1163
19. Czarnecka AM, Campanella C, Zummo G, Cappello F (2006) Mitochondrial chaperones in cancer: from molecular biology to clinical diagnostics. Cancer Biol Ther 5:714-720
20. DSouza GG, Wagle MA, Saxena V, Shah A (2011) Approaches for targeting mitochondriain cancer therapy. Biochim Biophys Acta 1807:689-696
21. Dang CV, Hamaker M, Sun P et al (2011) Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) 89:205-212
22. Debatin KM, Poncet D, Kroemer G (2002) Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21:8786-8803
23. DeBerardinis RJ, Cheng T (2010) Qs next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29:313-324
24. Deberardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008a) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11-20
25. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008b) Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18:54-61
26. Deichmann M, Kahle B, Benner A et al (2004) Somatic mitochondrial mutations in melanomaresection specimens. Int J Oncol 24:137-141
27. Dundas SR, Lawrie LC, Rooney PH, Murray GI (2005) Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Patholm 205:74-81
28. Elgadi KM, Meguid RA, Qian M et al (1999) Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics 1:51-62
29. Fan Y, Dickman KG, Zong WX (2010) Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem 285:7324-7333
30. Fantin VR, Leder P (2006) Mitochondriotoxic compounds for cancer therapy. Oncogene 25:4787-4797
31. Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers alink between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425-434
32. Felty Q, Roy D (2005) Estrogen, mitochondria, and growth of cancer and non-cancer cells. J Carcinog 4:1-18
33. Frezza C, Gottlieb E (2009) Mitochondriain cancer: not just innocent bystanders. Semin Cancer Biol 19:4-11
34. Frezza C, Zheng L, Folger O et al (2011) Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. doi: 10.1038/nature10363
35. Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25:4798-4811
36. Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondriafor cancer therapy. Nat Rev Drug Discov 9:447-464
37. Galluzzi L, Larochette N, Zamzami N, Kroemer G (2006) Mitochondriaas therapeutic targets for cancer chemotherapy. Oncogene 25:4812-4830
38. Gao P, Tchernyshyov I, Chang TC et al (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458:762-765
39. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-899
40. Gogvadze V, Orrenius S, Zhivotovsky B (2008) Mitochondriain cancer cells: what is so special about them? Trends Cell Biol 18:165-173
41. Gogvadze V, Orrenius S, Zhivotovsky B (2009) Mitochondriaas targets for cancer chemotherapy. Semin Cancer Biol 19:57-66
42. Green A, Beer P (2010) Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362:369-370
43. He Y, Wu J, Dressman DC et al (2010) Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 464:610-614
44. Herrnstadt C, Preston G, Howell N (2003) Errors, phantoms and otherwise, in human mtDNA sequences. Am J Hum Genet 72:1585-1586
45. Hoang AT, Huang J, Rudra-Ganguly N et al (2000) A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol 156:857-864
46. Horton TM, Petros JA, Heddi A et al (1996) Novel mitochondrial DNA deletion found in arenal cell carcinoma. Genes Chromosomes Cancer 15:95-101
47. Ishikawa K, Takenaga K, Akimoto M (2008) ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320:661-664
48. Jezek P, Plecitá-Hlavatá L, Smolková K, Rossignol R (2010) Distinctions and similarities of cell bioenergetics and the role of mitochondriain hypoxia, cancer, and embryonic development. Int J Biochem Cell Biol 42:604-622
49. Jiang P, Du W, Wang X et al (2011) p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13:310-316
50. Kallinowski F, Schlenger KH, Kloes M et al (1989) Tumor blood flow: the principal modulator of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in vivo. Int J Cancer 44:266-272
51. Keezer SM, Ivie SE, Krutzsch HC et al (2003) Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res 63:6405-6412
52. Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: abasic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257
53. Kim JW, Dang CV (2005) Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 30:142-150
54. Kondoh H, Lleonart ME, Gil J et al (2005) Glycolytic enzymes can modulate cellular life span. Cancer Res 65:177-185
55. Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburgs contributions to current concepts of cancer metabolism. Nat Rev Cancer 11:325-337
56. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancers Achilles heel. Cancer Cell 13:472-482
57. Le A, Cooper CR, Gouw AM et al (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 107:2037-2042
58. Lee HC, Li SH, Lin JC et al (2004) Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res 547:71-78
59. Liu H, Hu YP, Savaraj N et al (2001) Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 40: 5542-5547
60. Lowry OH, Berger SJ, Carter JG et al (1983) Diversity of metabolic patterns in human brain tumors: enzymes of energy metabolism and related metabolites and cofactors. J Neurochem 41:994-1010
61. Lueth M, von Deimling A, Pietsch T et al (2010) Medulloblastomaharbor somatic mitochondrial DNA mutations in the D-loop region. J Pediatr Hematol Oncol 32:156-159
62. Maddocks ODK, Vousden KH (2011) Metabolic regulation by p53. J Mol Med 89:237-245
63. Mai A, Massa S, Rotili D et al (2005) Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. Bioorg Med Chem Lett 15:4656-4661
64. Marín-Hernández A, Gallardo-Pérez JC, Ralph SJ et al (2009) HIF-1alphamodulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9:1084-1101
65. Marín-Hernández A, Gallardo-Pérez JC, Rodríguez-Enríquez S et al (2011) Modeling cancer glycolysis. Biochim Biophys Acta 1807:755-767
66. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB et al (2010) Oxidative stress in cancer associated fibroblasts drives tumor-stromaco-evolution: anew paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 9:3256-3276
67. Martinez-Outschoorn UE, Lin Z, Ko YH et al (2011) Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle 10:2521-2528
68. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancers double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777-4786
69. Meng M, Chen S, Lao T et al (2010) Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells. Cell Cycle 9:3921-3932
70. Michalik L, Desvergne B, Wahli W (2004) Peroxisome proliferator-activated receptor and cancers: complex stories. Nat Rev Cancer 4:61-70
71. Modica-Napolitano JS, Singh KK (2004) Mitochondrial dysfunction in cancer. Mitochondrion 4:755-762
72. Moll UM, Marchenko N, Zhang XK (2006) p53 and Nur77/TR3-transcription factors that directly target mitochondria for cell death induction. Oncogene 25:4725-4743
73. Moncada S, Erusalimsky JD (2002) Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol 3:214-220
74. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E (2007) Energy metabolism in tumor cells. FEBS J 274:1393-1418
75. Moreno-Sánchez R, Rodríguez-Enríquez S, Saavedra E et al (2009) The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells? Biofactors 35:209-225
76. Morrow G, Samson M, Michaud S, Tanguay RM (2004) Overexpression of the small mitochondrial Hsp22 extends Drosophilalife span and increases resistance to oxidative stress. FASEB J 18:598-599
77. Nakashima RA, Paggi MG, Pedersen PL (1984) Contributions of glycolysis and oxidative phosphorylation to adenosine 5-triphosphate production in AS-30D hepatomacells. Cancer Res 44(12 Pt 1):5702-5706
78. Naumov GN, Bender E, Zurakowski D et al (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316-325
79. Nomoto S, Yamashita K, Koshikawa K et al (2002) Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinomaand plasma. Clin Cancer Res 8:481-487
80. Parra-Bonilla G, Alvarez DF, Al-Mehdi AB et al (2010) Critical role for lactate dehydrogenase A in aerobic glycolysis that sustains pulmonary microvascular endothelial cell proliferation. Am J Physiol Lung Cell Mol Physiol 299:L513-L522
81. Parr RL, Dakubo GD, Crandall KA et al (2006) Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 8:312-319
82. Parrella P, Xiao Y, Fliss M et al (2001) Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res 61:7623-7626
83. Pockley AG (2001) Heat shock proteins in health and disease: therapeutic targets or therapeutics agents? Expert Rev Mol Med 3:1-21
84. Pollard PJ, Brière JJ, Alam NA et al (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alphain tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231-2239
85. Powers MV, Workman P (2007) Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 581: 3758-3769
86. Puzio-Kuter AM (2011) The role of p53 in metabolic regulation. Genes Cancer 2:385-391
87. Raj L, Ide T, Gurkar AU et al (2011) Selective killing of cancer cells by asmall molecule targeting the stress response to ROS. Nature 475:231-234
88. Richards FM, Watson A, Hickman JA (1988) Investigation of the effects of heat shock and agents which induce aheat shock response on the induction of differentiation of HL-60 cells. Cancer Res 48:6715-6720
89. Ritossa F (1962) A new puffing pattern induced by temperature shock and DNP in drosophila. Cell Mol Life Sci 18:571-573
90. Robey RB, Hay N (2009) Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19:25-31
91. Rodríguez-Enríquez S, Vital-González PA, Flores-Rodríguez FL et al (2006) Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells. Toxicol Appl Pharmacol 215: 208-217
92. Salas A, Yao YG, Macaulay V et al (2005) A critical reassessment of the role of mitochondriain tumorigenesis. PLoS Med 2:296
93. Sánchez-Aragó M, Cuezva JM (2011) The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. J Transl Med 9:19
94. Scatena R, Nocca G, Sole PD et al (1999) Bezafibrate as differentiating factor of human myeloid leukemiacells. Cell Death Differ 6:781-787
95. Scatena R, Bottoni P, Vincenzoni F et al (2003) Bezafibrate induces amitochondrial derangement in human cell lines. Intriguing effects for aperoxisome proliferator. Chem Res Tox 16:1440-1447
96. Scatena R, Bottoni P, Martorana GE et al (2007) Mitochondria, ciglitazone and liver: aneglected interaction in biochemical pharmacology. Eur J Pharmacol 567:50-58
97. Scatena R, Bottoni P, Pontoglio A et al (2008) Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs 17:1533-1545
98. Scatena R, Bottoni P, Pontoglio A, Giardina B (2010) Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy. Proteomics Clin Appl 4:143-158
99. Schmitt E, Gehrmann M, Brunet M et al (2007) Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 81:15-27
100. Semenza GL (2007) Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 405:1-9
101. Semenza GL (2009) Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19:12-16
102. Shanware NP, Mullen AR, DeBerardinis RJ, Abraham RT (2011) Glutamine: pleiotropic roles in tumor growth and stress resistance. J Mol Med (Berl) 89:229-236
103. Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18:598-608
104. Smith DF, Whitesell L, Katsanis E (1998) Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol Res 50:493-513
105. Smolková K, Bellance N, Scandurra F et al (2010) Mitochondrial bioenergetic adaptations of breast cancer cells to aglycemiaand hypoxia. J Bioenerg Biomembr 42:55-67
106. Soti C, Nagy E, Giricz Z et al (2005) Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 146:769-780
107. Sur R, Lyte PA, Southall MD (2008) Hsp27 regulates proinflammatory mediator release in keratinocytes by modulating NF-kappaB signaling. J Invest Dermatol 128:1116-1122
108. Takahashi A, Ohtani N, Yamakoshi K (2006) Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 8:1291-1297
109. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-1033
110. Vander Heiden MG, Christofk HR, Schuman E et al (2010) Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 79:1118-1124
111. Wada T, Tanji N, Ozawa A et al (2006) Mitochondrial DNA mutations and 8-hydroxy-2′-deoxyguanosine Content in Japanese patients with urinary bladder and renal cancers. Anticancer Res 26:3403-3408
112. Wadhwa R, Ryu J, Gao R et al (2010) Proproliferative functions of Drosophilasmall mitochondrial heat shock protein 22 in human cells. J Biol Chem 285:3833-3839
113. Wang XY, Chen X, Oh HJ et al (2000) Characterization of native interaction of hsp110 with hsp25 and hsc70. FEBS Lett 465:98-102
114. Warburg O (1925) Über den Stoffwechsel der Carcinomzelle. Klin Wochenschr 4:534-536
115. Weinberg F, Hamanaka R, Wheaton WW et al (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107:8788-8793
116. Wellen KE, Hatzivassiliou G, Sachdeva UM et al (2009) ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324:1076-1080
117. Wu CW, Yin PH, Hung WY et al (2005) Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer 44:19-28
118. Wu M, Neilson A, Swift AL et al (2007) Multiparameter metabolic analysis reveals aclose link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 292:C125-C136
119. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
120. Yeung SJ, Pan J, Lee MH (2008) Roles of p53, MYC and HIF-1 in regulating glycolysis-the seventh hallmark of cancer. Cell Mol Life Sci 65:3981-3999
121. Zhang E, Zhang C, Su Y et al (2011) Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy. Drug Discov Today 16:140-146
122. Zhou J, Schmid T, Frank R et al (2004) PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alphafrom pVHL-independent degradation. J Biol Chem 279:13506-13513
123. Zu XL, Guppy M (2004) Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 313:459-465